Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome

The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1% (13/22) and 68.2% (15/22), respectively. The rates in the final global improvement was 68.2% (15/22). The rates in the diarrhea and constipation predominant cases were 66.7% (12/18) and 75.0% (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0% (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.